Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)
Titel:
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)
Auteur:
Xu, Jianming Shen, Lin Li, Jie Zhou, Zhiwei Bai, Chunmei Li, Zhiping Chi, Yihebali Li, Enxiao Yu, Xianjun Xu, Nong Bai, Yuxian Wang, Xiuwen Yuan, Xianglin Liu, Tianshu Yin, Yongmei Chen, Jia Hu, Hanguang Li, Xingya Xiu, Dianrong Zhang, Tao Lou, Wenhui Ying, Jieer Qin, Shukui Deng, Yanhong Tao, Min Cheng, Ying Fan, Songhua Luo, Xian Guo, Xiaojun Shi, Michael M. Su, Weiguo